| abstract |
The present invention relates to antibodies directed to the CD20 antigen and to uses of such antibodies. In particular, to fully human monoclonal antibodies directed to the CD20 antigen. Also described are nucleotide coding sequences, and amino acid sequences comprising, light and heavy chain immunoglobulin molecules, particularly sequences corresponding to contiguous light and heavy chain sequences that cross the regions of structure and / or the regions that determine the Complementarity (CDR), specifically from FR1 to FR4 or CDR1 to CDR3. Hydribomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also described. |